Current role and future aspects of topotecan in relapsed ovarian cancer

References

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA:Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
   PubMed Web of Science ®Google Scholar
• Ahmad T, Gore M. Review of the use of topotecan in ovarian carcinoma. Expert opinion on pharmacotherapy 2004;5:2333-40
   PubMed Web of Science ®Google Scholar
• Obel J, Fleming G. Topotecan in the treatment of ovarian cancer. Expert Rev Obstet Gynecol 2006;1:149-58
   Google Scholar
• Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 2006;32:875-86
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Aghajanian CA, Alberts DS, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol 2005;96:10-18
   PubMed Web of Science ®Google Scholar
• Abushahin F, Singh DK, Lurain JR, et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 2008;108:53-7
   PubMed Web of Science ®Google Scholar
• Kristensen GB, Vergote I, Stuart G, et al. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer 2003;13 (Suppl 2):172-7
   PubMed Web of Science ®Google Scholar
• du Bois A, Weber B, Rochon J, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 2006;24:1127-35
   PubMed Web of Science ®Google Scholar
• du Bois A, Belau A, Wagner U, et al. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecol Oncol 2005;96:444-51
   PubMed Web of Science ®Google Scholar
• Hoskins PJ, Vergote I, Stuart G, et al. A phase III trial of cisplatin plus topotecan followed by paclitaxel plus carboplatin versus standard carboplatin plus paclitaxel as first-line chemotherapy in women with newly diagnosed advanced epithelial ovarian cancer (EOC) (OV.16). A Gynecologic Cancer Intergroup Study of the NCIC CTG, EORTC GCG, and GEICO. J Clin Oncol 2008;26 (20S): Abstract LBA 5505
   Google Scholar
• Gordon AN, Asmar L, Messing MJ, et al. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol 2004;94:533-9
   PubMed Web of Science ®Google Scholar
• Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996;14:3056-61
   PubMed Web of Science ®Google Scholar
• Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-7
   PubMed Web of Science ®Google Scholar
• Swisher EM, Mutch DG, Rader JS, et al. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997;66:480-6
   PubMed Web of Science ®Google Scholar
• Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998;16:3345-52
   PubMed Web of Science ®Google Scholar
• McGuire WP, Blessing JA, Bookman MA, et al. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2000;18:1062-7
   PubMed Web of Science ®Google Scholar
• Safra T, Menczer J, Bernstein R, et al. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 2007;105:205-10
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Gore M, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-93
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W, Lane SR, Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004;15:100-3
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-22
   PubMed Web of Science ®Google Scholar
• Meier W, Dubois A, Kuhn W, et al. Topotecan vs treosulfan in recurrent ovarian cancer (OC) after initial therapy with platinum and paclitaxel. A prospective randomized phase III study. Proc Am Soc Clin Oncol 2003;22: Abstract 1810
   Google Scholar
• Vandenput I, Amant F, Neven P, et al. Effectiveness of weekly topotecan in patients with recurrent epithelial ovarian cancer. Int J Gynecol Cancer 2007;17:83-7
   PubMed Web of Science ®Google Scholar
• Clarke-Pearson DL, Van Le L, Iveson T, et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001;19:3967-75
   PubMed Web of Science ®Google Scholar
• Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002;38:57-63
   PubMed Web of Science ®Google Scholar
• Markman M, Webster K, Zanotti K, et al. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 2004;95:109-13
   PubMed Web of Science ®Google Scholar
• Tillmanns TD, Buller R, Stewart CF, et al. Daily oral topotecan: Utilization of a metronomic dosing schedule to treat recurrent or persistent solid tumors. J Clin Oncol 2008;26: Abstract 2571
   Google Scholar
• Gralla RJ. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist 2004;9 (Suppl 6):14-24
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Spriggs D, Levin J, et al. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist 2005;10:686-94
   PubMed Web of Science ®Google Scholar
• Herzog TJ. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist 2002;7 (Suppl 5):3-10
   PubMed Web of Science ®Google Scholar
• Peng LH, Chen XY, Wu TX. Topotecan for ovarian cancer. Cochrane Database Syst Rev (Online) 2008: CD005589
   PubMedGoogle Scholar
• Garst J. Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. Exp Opin Drug Safe 2007;6:53-62
   PubMed Web of Science ®Google Scholar
• Goldwasser F, Buthaud X, Gross M, et al. Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients. Anti-cancer Drugs 1999;10:263-5
   PubMed Web of Science ®Google Scholar
• Eckardt JR. Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 2004;9 (Suppl 6):25-32
   PubMed Web of Science ®Google Scholar
• Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. Oncologist 2002; (7 Suppl 5):29-35
   PubMed Web of Science ®Google Scholar
• Homesley H, Benigno B, Williams J, et al. A phase I study of weekly topotecan and paclitaxel in previously treated epithelial ovarian carcinoma patients. Gynecol Oncol 2002;87:171-7
   PubMed Web of Science ®Google Scholar
• Brown JV, 3rd, Rettenmaier MA, Lopez KL, et al. A phase II, multicenter trial of weekly topotecan in patients with recurrent platinum-sensitive epithelial cancers of the ovary and peritoneum. Int J Gynecol Cancer 2008;18:249-54
   PubMed Web of Science ®Google Scholar
• Largillier R, Valenza B, Ferrero JM, et al. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy. Oncology 2007;73:177-84
   PubMed Web of Science ®Google Scholar
• Spannuth WA, Leath CA, 3rd, Huh WK, et al. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 2007;104:591-5
   PubMed Web of Science ®Google Scholar
• Le T, Hopkins L, Baines KA, et al. Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer. Int J Gynecol Cancer 2008;18:428-31
   PubMed Web of Science ®Google Scholar
• O'Malley DM, Azodi M, Makkenchery A, et al. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2005;98:242-8
   PubMed Web of Science ®Google Scholar
• Sehouli J, Oskay-Oezcelik G, Stengel D, et al. Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO). J Clin Oncol 2007;25 (18S): Abstract 5526
   Google Scholar
• Sehouli J, Stengel D, Oskay-Oezcelik G, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2008;26:3176-82
   PubMed Web of Science ®Google Scholar
• Scarfone G, Scambia G, Raspagliesi F, et al. A multicenter, randomized, phase III study comparing paclitaxel/carboplatin (PC) versus topotecan/paclitaxel/carboplatin (TPC) in patients with stage III (residual tumor >1 cm after primary surgery) and IV ovarian cancer (OC). J Clin Oncol 2006;24 (18S): Abstract 5003
   Web of Science ®Google Scholar
• Pfisterer J, Weber B, Reuss A, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006;98:1036-45
   PubMed Web of Science ®Google Scholar
• De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 2004;22:2635-42
   PubMed Web of Science ®Google Scholar
• Bookman MA. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol 2006;24 (18S): Abstract 5002
   PubMed Web of Science ®Google Scholar
• Verhaar-Langereis M, Karakus A, van Eijkeren M, et al. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006;16:65-70
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Malamos NA, Aravantinos G, et al. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer Chemother Pharmacol 2007;60:123-8
   PubMed Web of Science ®Google Scholar
• Sehouli J, Stengel D, Oskay G, et al. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol 2002;13:1749-55
   PubMed Web of Science ®Google Scholar
• Chiara S, Tognoni A, Pastrone I, et al. Topotecan and ifosfamide as salvage treatment in advanced ovarian cancer. Gynecol Oncol 2004;93:474-8
   PubMed Web of Science ®Google Scholar
• Hanjani P, Nolte S, Shahin MS. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecol Oncol 2002;85:278-84
   PubMed Web of Science ®Google Scholar
• Koensgen D, Stengel D, Belau A, et al. Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study. Cancer Chemother Pharmacol 2008;62:393-400
   PubMed Web of Science ®Google Scholar
• Vecchione F, Fruscio R, Dell'Anna T, et al. A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer. Int J Gynecol Cancer 2007;17:367-72
   PubMed Web of Science ®Google Scholar
• Elkas JC, Winter WE, 3rd, Chernofsky MR, et al. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Gynecol Oncol 2007;104:422-7
   PubMed Web of Science ®Google Scholar
• McGonigle KF, Muntz HG, Vuky JL, et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC). J Clin Oncol 2008;26: Abstract 5551
   Google Scholar
• Schwartzberg LS, Stewart CF, Schaiquevich P, et al. Phase I dosage-finding and pharmacokinetic (PK) study of intravenous topotecan and oral erlotinib in patients (pts) with refractory solid tumors. J Clin Oncol 2008;20: Abstract 2549
   Google Scholar
• Downs Jr LS, Judson PL, Argenta PA, et al. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008;112:331-9
   PubMed Web of Science ®Google Scholar
• Molina JR, Kaufmann SH, Reid JM, et al. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clin Cancer Res 2008;14:7900-7908
   PubMed Web of Science ®Google Scholar